Episode Player
RADIOPHARM THERANOSTICS LTD (RAD) - When Earlier Detection Becomes Better Survival
ASX BRIEFS
A scan that finds brain metastases earlier could change the whole treatment timeline, and that is exactly what we dig into with Riccardo Canevari, CEO and Managing Director of Radiopharm Theranostics. We walk through how a clinical-stage ASX biopharmaceutical company designs radiopharmaceuticals for oncology, and why “theranostics” is more than a buzzword when patients need faster, clearer answers.
Riccardo breaks down the company’s two-platform approach: small molecules for imaging that can penetrate tissue and light up tiny tumours, and larger antibody-based therapies that stay in the body long enough to deliver a targeted radioactive payload. We talk about RAD 101 and its interim Phase 2B results in recurrent brain metastases, including strong concordance with MRI and the bigger goal of proving clinical value by detecting more disease earlier. Earlier detection can mean earlier treatment, which can ultimately mean better outcomes.
We also cover the first patient dosed in the Phase 1 RAD 404 study for advanced prostate cancer, using a Terbium‑161 radio labelled antibody designed to damage cancer cell DNA. From there, we zoom out to the broader pipeline, including ongoing Australian studies such as RAD 202 and RAD 204 across lung and breast cancers, and how the team thinks about prioritisation when multiple trials are running at once. Finally, we look at next steps towards a pivotal Phase 3 program, FDA alignment, and what fast track designations could mean as the company moves towards late-stage registrational pathways.
If you found this useful, subscribe for more ASX biotech conversations, share the episode with a mate, and leave a review so more people can find the show.
